Compounded Semaglutide: What It Is, Is It Safe, and How to Get It

Semaglutide — the active ingredient in Ozempic and Wegovy — has transformed weight loss medicine, but its brand-name price tag remains out of reach for millions of people. Compounded semaglutide has emerged as a legal, significantly more affordable alternative that uses the same active molecule to deliver clinically meaningful results.

What Is Compounded Semaglutide?

Compounding is the practice of a licensed pharmacy preparing a custom medication — often combining, altering, or recreating drug formulations — for individual patients. It's a practice with roots going back centuries, and in the United States it is regulated by both the FDA and state pharmacy boards.

Compounded semaglutide is semaglutide — the same glucagon-like peptide-1 (GLP-1) receptor agonist that makes Ozempic and Wegovy work — prepared by a licensed 503A or 503B compounding pharmacy. Rather than the branded, commercially manufactured injection pen, you receive a vial and syringe containing the same active ingredient, typically at a fraction of the cost.

It's important to understand what compounding is not: it is not a generic drug. Generics are copies of brand-name drugs approved through the FDA's abbreviated new drug application (ANDA) process. Compounded medications do not go through that approval process, which is why FDA oversight of the compounding pharmacy itself — and the prescribing provider's judgment — is especially important.

How Does Semaglutide Work?

Semaglutide mimics a hormone called GLP-1 that your gut naturally releases after eating. GLP-1 signals your pancreas to release insulin, slows gastric emptying (so food stays in your stomach longer), and — critically for weight loss — acts on hunger and reward centers in the brain to significantly reduce appetite.

In the landmark STEP 1 trial published in the New England Journal of Medicine, participants taking 2.4 mg weekly semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in the placebo group. For someone weighing 220 pounds, that's roughly 33 pounds of weight loss.

Those results — and a growing body of supporting evidence — are what drive demand. Novo Nordisk, the manufacturer of both Ozempic and Wegovy, has struggled to keep up. That supply-demand imbalance is central to the story of compounded semaglutide.

The 2026 FDA Landscape: What You Need to Know

The regulatory environment around compounded semaglutide shifted significantly in early 2025 and has continued to evolve into 2026. Understanding the current status is critical before you begin any treatment.

The Shortage Declaration and Its Aftermath

From mid-2022 through early 2025, the FDA listed both semaglutide injection products (Ozempic and Wegovy) on its official drug shortage list. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to prepare copies of commercially available drugs when those drugs appear on the shortage list — making compounded semaglutide broadly legal during that period.

In early 2025, the FDA removed semaglutide from the shortage list, triggering a compliance window during which compounding pharmacies were given time to wind down production. That timeline prompted legal challenges from compounding pharmacy trade groups and telehealth companies who argued the shortage had not genuinely resolved for all patients.

As of 2026, the legal landscape is nuanced. 503B outsourcing facilities — larger, FDA-registered facilities held to more stringent manufacturing standards than traditional 503A pharmacies — operate under specific provisions that may still permit compounding of semaglutide under certain circumstances. Meanwhile, 503A pharmacies serving individual patient prescriptions continue to operate in a space that is subject to ongoing regulatory interpretation and potential enforcement action.

This is precisely why the provider you work with matters enormously. A reputable telehealth practice like Truventa Medical works only with vetted, compliant compounding pharmacies and stays current on regulatory guidance so patients are never caught in a gray area.

Is Compounded Semaglutide FDA-Approved?

No — and this distinction matters. The FDA approves drug products, not compounded preparations. What is regulated is the pharmacy doing the compounding and the conditions under which it operates. A compound prepared by an accredited 503B facility that meets Current Good Manufacturing Practice (CGMP) standards carries meaningfully different quality assurances than one prepared by a low-quality online pharmacy with no accountability.

Red flags to watch for include pharmacies that don't require a valid prescription, that advertise semaglutide as a "peptide" to avoid regulation, or that have no licensed prescriber involvement in the clinical decision. These are not minor technicalities — they are indicators of unsafe practices.

Is Compounded Semaglutide Safe?

This is the question patients ask most often, and the honest answer is: it depends heavily on where it comes from and who is overseeing your care.

The FDA has issued warnings about compounded semaglutide products that contain semaglutide sodium or semaglutide acetate — salt forms of the molecule that are chemically distinct from the semaglutide base used in Ozempic and Wegovy. These salt forms have not been clinically validated, and there is no data demonstrating they work the same way or carry the same safety profile. The base form of semaglutide, the kind used in FDA-approved products, is what you want.

A compounding pharmacy using pharmaceutical-grade semaglutide base, operating under CGMP conditions, with proper sterility testing and potency verification, produces a product that is chemically equivalent to what's in Wegovy. The risks in that scenario are essentially the same as with the brand-name drug.

Side Effects to Expect

Regardless of whether you use branded or compounded semaglutide, the side effect profile is driven by the molecule itself. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most pronounced early in treatment and typically improve as the body adapts. Starting at a low dose and titrating slowly — a standard clinical approach — significantly reduces GI burden.

Less common but more serious risks include pancreatitis, gallbladder disease, and a theoretical concern about thyroid C-cell tumors seen in rodent studies (though this has not been demonstrated in humans). People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) should not use GLP-1 medications.

A licensed provider conducting a proper intake evaluation will screen for these contraindications before prescribing. That evaluation — not skipping it — is one of the most important safety features of any legitimate semaglutide program.

Cost Comparison: Compounded vs. Brand Name

Brand-name semaglutide is expensive. Wegovy carries a list price of approximately $1,350 per month without insurance. Even patients with commercial insurance often find coverage restricted or subject to high prior authorization hurdles. Ozempic, though approved for type 2 diabetes, is frequently prescribed off-label for weight loss at a similar price point.

Compounded semaglutide, by contrast, typically runs $150–$400 per month depending on dose, pharmacy, and the telehealth program's structure. That's a cost difference of roughly 70–90%, which for many patients is the difference between accessing treatment and not accessing it at all.

There are legitimate reasons brand-name products cost more — research and development, clinical trials, manufacturing at commercial scale, post-market surveillance. But for patients who cannot access those products due to cost or ongoing supply disruptions, a well-sourced compounded alternative represents real clinical value.

How to Get Compounded Semaglutide Through a Licensed Provider

The safest and most effective path to compounded semaglutide is through a licensed medical provider who conducts a thorough evaluation, writes a valid prescription, and monitors your progress over time. Here's what that process looks like when done correctly.

Step 1: Medical Evaluation

A provider should review your health history, current medications, BMI, and any contraindications before prescribing semaglutide. Ideal candidates typically have a BMI of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher regardless of comorbidities — mirroring the criteria from the STEP trials.

Step 2: Prescription and Pharmacy

Your provider sends a valid prescription to a vetted compounding pharmacy. At Truventa Medical, we work exclusively with licensed 503A and 503B facilities that use pharmaceutical-grade semaglutide base, conduct sterility and potency testing, and meet or exceed state and federal compounding standards. Your medication ships directly to you in most states.

Step 3: Titration and Monitoring

Semaglutide is started at a low dose — typically 0.25 mg weekly — and increased every four weeks as tolerated. Having a provider who adjusts your dose based on your response, manages side effects, and checks in on your progress is what separates a good program from a bad one. Weight loss medication without ongoing clinical support is not good medicine.

Through a platform like Truventa Medical, follow-up consultations, messaging with your care team, and dose adjustments are built into the program — not treated as extras.

Who Is a Good Candidate?

You may be a strong candidate for semaglutide if you:

• Have a BMI of 30 or higher, or 27+ with a condition like type 2 diabetes, hypertension, or high cholesterol
• Have tried diet and exercise without achieving or sustaining significant weight loss
• Do not have a history of medullary thyroid carcinoma, MEN2, or pancreatitis
• Are not pregnant or planning to become pregnant
• Are not currently taking other GLP-1 medications

Even if you meet these criteria, only a licensed provider can determine whether semaglutide is appropriate for you as an individual. Factors like kidney function, current medications (particularly insulin), and mental health history all factor into that decision.

The Bottom Line

Compounded semaglutide is a legitimate, cost-effective option for patients who want the benefits of GLP-1 therapy without the brand-name price tag — provided it comes from a reputable source and is prescribed and monitored by a licensed provider. The molecule works. The science is solid. What varies is the quality of the pharmacy, the rigor of the prescribing process, and the level of ongoing clinical support you receive.

Avoid any program that skips the medical evaluation, uses non-base forms of semaglutide, or can't tell you exactly where its pharmacy is located and how it's regulated. Those are not corners worth cutting.

If you're ready to explore whether compounded semaglutide is right for you, the next step is a real consultation with a real provider — and that's exactly what Truventa Medical is built to deliver.